Clinical Scorecard: Heart Failure Among Patients Recently Diagnosed with Atrial Fibrillation: Insights from the GLORIA-AF Phase III Registry
At a Glance
Category
Detail
Condition
Atrial fibrillation (AF) coexisting with congestive heart failure (CHF)
Key Mechanisms
Shared risk factors (hypertension, coronary artery disease, diabetes, obesity) create a vicious cycle increasing the likelihood of AF and CHF co-occurrence; CHF influences stroke risk and anticoagulation decisions in AF
Target Population
Adults with recent diagnosis of non-valvular AF and CHA2DS2-VASc score ≥ 1
Care Setting
Real-world, multicenter, global registry setting (GLORIA-AF Phase III)
Key Highlights
CHF was present in approximately 22% of patients with recent AF diagnosis.
Patients with CHF and LVEF ≤ 40% had higher odds of receiving oral anticoagulants compared to those without CHF.
CHF in AF patients was associated with a twofold increased risk of all-cause death and major adverse cardiovascular events over 3 years.
Guideline-Based Recommendations
Diagnosis
Identify CHF presence and categorize heart failure by left ventricular ejection fraction (LVEF ≤ 40%, 41–49%, ≥ 50%) in patients with recent AF diagnosis.
Management
Consider oral anticoagulation in AF patients with CHF, especially those with LVEF ≤ 40%, with preference for vitamin K antagonists over non-vitamin K oral anticoagulants in CHF patients.
Use CHA2DS2-VASc score including CHF as a stroke risk factor to guide anticoagulation decisions.
Monitoring & Follow-up
Monitor for adverse outcomes including all-cause mortality, major adverse cardiovascular events, thromboembolism, and major bleeding during follow-up.
Risks
Recognize that AF patients with CHF have higher risks of death, cardiovascular events, thromboembolism, and bleeding, particularly those with reduced LVEF (≤ 40%).
Patient & Prescribing Data
Patients with recent AF diagnosis and coexisting CHF, stratified by LVEF status
Patients with CHF and reduced LVEF (≤ 40%) are more likely to receive oral anticoagulants; however, non-vitamin K oral anticoagulants are less frequently used in CHF patients regardless of LVEF.
Clinical Best Practices
Assess LVEF to guide anticoagulation therapy choices in AF patients with CHF.
Incorporate CHF status into stroke risk stratification using CHA2DS2-VASc score.
Provide intensified management and follow-up for AF patients with CHF due to their higher risk profile.
Prefer vitamin K antagonists over non-vitamin K oral anticoagulants in CHF patients until further evidence clarifies optimal anticoagulant choice.
by Bernadette Corica, Giulio Francesco Romiti, Marco Proietti, Giuseppe Boriani, Brian Olshansky, Menno V Huisman, Gregory Y H Lip, on behalf of the GLORIA-AF Investigators
